ESCMID guideline for the diagnosis and treatment of biofilm infections 2014

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. / Høiby, N; Bjarnsholt, Thomas; Moser, C; Bassi, G L; Coenye, T; Donelli, G; Hall-Stoodley, L; Holá, V; Imbert, C; Kirketerp-Møller, K; Lebeaux, D; Oliver, A; Ullmann, A J; Williams, C; ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli.

In: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 21, No. Suppl. 1, 14.01.2015, p. s1-s25.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Høiby, N, Bjarnsholt, T, Moser, C, Bassi, GL, Coenye, T, Donelli, G, Hall-Stoodley, L, Holá, V, Imbert, C, Kirketerp-Møller, K, Lebeaux, D, Oliver, A, Ullmann, AJ, Williams, C & ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli 2015, 'ESCMID guideline for the diagnosis and treatment of biofilm infections 2014', Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 21, no. Suppl. 1, pp. s1-s25. https://doi.org/10.1016/j.cmi.2014.10.024

APA

Høiby, N., Bjarnsholt, T., Moser, C., Bassi, G. L., Coenye, T., Donelli, G., Hall-Stoodley, L., Holá, V., Imbert, C., Kirketerp-Møller, K., Lebeaux, D., Oliver, A., Ullmann, A. J., Williams, C., & ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli (2015). ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 21(Suppl. 1), s1-s25. https://doi.org/10.1016/j.cmi.2014.10.024

Vancouver

Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015 Jan 14;21(Suppl. 1):s1-s25. https://doi.org/10.1016/j.cmi.2014.10.024

Author

Høiby, N ; Bjarnsholt, Thomas ; Moser, C ; Bassi, G L ; Coenye, T ; Donelli, G ; Hall-Stoodley, L ; Holá, V ; Imbert, C ; Kirketerp-Møller, K ; Lebeaux, D ; Oliver, A ; Ullmann, A J ; Williams, C ; ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli. / ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. In: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015 ; Vol. 21, No. Suppl. 1. pp. s1-s25.

Bibtex

@article{b8a85505d9234a568e9833d38c30e7ae,
title = "ESCMID guideline for the diagnosis and treatment of biofilm infections 2014",
abstract = "Biofilms cause chronic infections in tissues or by developing on the surfaces of medical devices. Biofilm infections persist despite both antibiotic therapy and the innate and adaptive defence mechanisms of the patient. Biofilm infections are characterized by persisting and progressive pathology due primarily to the inflammatory response surrounding the biofilm. For this reason, many biofilm infections may be difficult to diagnose and treat efficiently. It is the purpose of the guideline to bring the current knowledge of biofilm diagnosis and therapy to the attention of clinical microbiologists and infectious disease specialists. Selected hallmark biofilm infections in tissues (e.g. cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. orthopaedic alloplastic devices, endotracheal tubes, intravenous catheters, indwelling urinary catheters, tissue fillers) are the main focus of the guideline, but experience gained from the biofilm infections included in the guideline may inspire similar work in other biofilm infections. The clinical and laboratory parameters for diagnosing biofilm infections are outlined based on the patient's history, signs and symptoms, microscopic findings, culture-based or culture-independent diagnostic techniques and specific immune responses to identify microorganisms known to cause biofilm infections. First, recommendations are given for the collection of appropriate clinical samples, for reliable methods to specifically detect biofilms, for the evaluation of antibody responses to biofilms, for antibiotic susceptibility testing and for improvement of laboratory reports of biofilm findings in the clinical microbiology laboratory. Second, recommendations are given for the prevention and treatment of biofilm infections and for monitoring treatment effectiveness. Finally, suggestions for future research are given to improve diagnosis and treatment of biofilm infections.",
author = "N H{\o}iby and Thomas Bjarnsholt and C Moser and Bassi, {G L} and T Coenye and G Donelli and L Hall-Stoodley and V Hol{\'a} and C Imbert and K Kirketerp-M{\o}ller and D Lebeaux and A Oliver and Ullmann, {A J} and C Williams and {ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli}",
note = "Copyright {\textcopyright} 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.",
year = "2015",
month = jan,
day = "14",
doi = "10.1016/j.cmi.2014.10.024",
language = "English",
volume = "21",
pages = "s1--s25",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier",
number = "Suppl. 1",

}

RIS

TY - JOUR

T1 - ESCMID guideline for the diagnosis and treatment of biofilm infections 2014

AU - Høiby, N

AU - Bjarnsholt, Thomas

AU - Moser, C

AU - Bassi, G L

AU - Coenye, T

AU - Donelli, G

AU - Hall-Stoodley, L

AU - Holá, V

AU - Imbert, C

AU - Kirketerp-Møller, K

AU - Lebeaux, D

AU - Oliver, A

AU - Ullmann, A J

AU - Williams, C

AU - ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli

N1 - Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

PY - 2015/1/14

Y1 - 2015/1/14

N2 - Biofilms cause chronic infections in tissues or by developing on the surfaces of medical devices. Biofilm infections persist despite both antibiotic therapy and the innate and adaptive defence mechanisms of the patient. Biofilm infections are characterized by persisting and progressive pathology due primarily to the inflammatory response surrounding the biofilm. For this reason, many biofilm infections may be difficult to diagnose and treat efficiently. It is the purpose of the guideline to bring the current knowledge of biofilm diagnosis and therapy to the attention of clinical microbiologists and infectious disease specialists. Selected hallmark biofilm infections in tissues (e.g. cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. orthopaedic alloplastic devices, endotracheal tubes, intravenous catheters, indwelling urinary catheters, tissue fillers) are the main focus of the guideline, but experience gained from the biofilm infections included in the guideline may inspire similar work in other biofilm infections. The clinical and laboratory parameters for diagnosing biofilm infections are outlined based on the patient's history, signs and symptoms, microscopic findings, culture-based or culture-independent diagnostic techniques and specific immune responses to identify microorganisms known to cause biofilm infections. First, recommendations are given for the collection of appropriate clinical samples, for reliable methods to specifically detect biofilms, for the evaluation of antibody responses to biofilms, for antibiotic susceptibility testing and for improvement of laboratory reports of biofilm findings in the clinical microbiology laboratory. Second, recommendations are given for the prevention and treatment of biofilm infections and for monitoring treatment effectiveness. Finally, suggestions for future research are given to improve diagnosis and treatment of biofilm infections.

AB - Biofilms cause chronic infections in tissues or by developing on the surfaces of medical devices. Biofilm infections persist despite both antibiotic therapy and the innate and adaptive defence mechanisms of the patient. Biofilm infections are characterized by persisting and progressive pathology due primarily to the inflammatory response surrounding the biofilm. For this reason, many biofilm infections may be difficult to diagnose and treat efficiently. It is the purpose of the guideline to bring the current knowledge of biofilm diagnosis and therapy to the attention of clinical microbiologists and infectious disease specialists. Selected hallmark biofilm infections in tissues (e.g. cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. orthopaedic alloplastic devices, endotracheal tubes, intravenous catheters, indwelling urinary catheters, tissue fillers) are the main focus of the guideline, but experience gained from the biofilm infections included in the guideline may inspire similar work in other biofilm infections. The clinical and laboratory parameters for diagnosing biofilm infections are outlined based on the patient's history, signs and symptoms, microscopic findings, culture-based or culture-independent diagnostic techniques and specific immune responses to identify microorganisms known to cause biofilm infections. First, recommendations are given for the collection of appropriate clinical samples, for reliable methods to specifically detect biofilms, for the evaluation of antibody responses to biofilms, for antibiotic susceptibility testing and for improvement of laboratory reports of biofilm findings in the clinical microbiology laboratory. Second, recommendations are given for the prevention and treatment of biofilm infections and for monitoring treatment effectiveness. Finally, suggestions for future research are given to improve diagnosis and treatment of biofilm infections.

U2 - 10.1016/j.cmi.2014.10.024

DO - 10.1016/j.cmi.2014.10.024

M3 - Journal article

C2 - 25596784

VL - 21

SP - s1-s25

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - Suppl. 1

ER -

ID: 135151844